Physician profile
Sindhu Kaitha
NPI 1821309964
$2,543.78
in general payments reported to CMS, 2019-2025
17 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $120 · 2021: $228 · 2022: $410 · 2023: $380 · 2024: $428 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.73 | 2019-2025 | |
| Janssen Biotech, INC. | $216.02 | 2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $208.56 | 2021-2024 | Livdelzi |
| Amgen INC. | $125.00 | 2023 | Tavneos |
| Intercept Pharmaceuticals, INC. | $120.66 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $104.74 | 2019-2021 | |
| Madrigal Pharmaceuticals | $67.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $61.83 | 2025 | Zenpep, Vowst |
| Redhill Biopharma INC. | $56.88 | 2022-2023 | Movantik, Talicia, Aemcolo |
| Pfizer INC. | $51.80 | 2019-2023 | |
| Ardelyx, INC. | $49.78 | 2025 | Ibsrela |
| Olympus America INC. | $36.28 | 2025 | Hanarostent Esophagus Tts(Ccc) |
| Nestle Healthcare Nutrition INC. | $22.15 | 2022 | |
| Novo Nordisk INC | $17.04 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $16.88 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Perspectum Diagnostics LTD | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $13.55 | 2024 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Kaitha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.